Mendus has enroled the first 10 patients in the phase Ib VITAL-CML study.
* Positive organic growth will take time * We slightly lower our sales estimates due to a reduction ...
* Order book at a record high ~SEK 640m... * ...with ~SEK 225m expected to roll out in the next 12m ...
* A better mix of growth drivers * Costs reflect investments in the organisation * EV/adj.
Redeye returns with an update on Ascelia after the Q2 report, which contained few surprises.
* Sales SEK 20m vs. ABGSCe 26m, EBIT roughly in line * Cost control holds EBIT despite soft top line...
Redeye considers I-Tech’s Q2 report to be very solid.
* Sales SEK 10m (vs. ABGSCe 16m) driven by Coating Services * No system deliveries in Q2, but two IC...
AVTECH's Q2 landed on the preannounced figures — net sales 1% above Redeye's estimate, EBITDA 13% be...
Sales +21% vs. ABGSCe, EBIT SEK 21m vs. ABGSCe 13m Easy comps, but +91% organic growth still very st...
Angler Gaming delivered a strong Q2, with revenue of EUR 8.
Hacksaw has announced the appointment of Ana Vrabic Verdir as permanent CEO, following her role as i...
Tonies delivered a strong Q2, with group revenue of € 117m, +49% yoy (cc) ahead of consensus (€108m)...
Redeye comments on Better Collective’s Q2-results which were above our forecast, owing to a slightly...
Ferroamp’s Q2 report provides further evidence that the commercial ramp is gaining traction, with sa...
Redeye comments on Cheffelo's Q2 2026 report, showing 24% net sales growth in local currency to SEK3...
Investors House's Q2 report was broadly in line with our expectations, with the Real Estate segment ...
Redeye provides an update following Neola Medical’s Q2 2026 report.
* Q2: +6% sales growth, 2.2% EBITDA margin * '26e EBITDA down SEK 9m * Guarding continues to take st...
Redeye interviewed Optomed’s CEO, Juho Himberg, following the company’s Q2 2026 report.
